[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"William Marsh Rice University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":125},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,50,75,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635571","phase-4-combatting-muscle-loss-in-obese-adult-patients-on-glp-1-medications-through-dietary-counseling-and-exercise-during-treatment-evaluates-whether-a-12-week-exercise-and-individualized-nutrition-program-can-reduce-muscle-and-bone-loss-and-improve-strength-fitness-and-function-in-obese-adults-on-glp-1-100635571",false,"NCT07554417","Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1","Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment","Inclusion Criteria:\n\n* Age between 40 and 55 years\n* Body Mass Index (BMI) greater than 30\n* Body fat percentage greater than 30% for males and 40% for females\n* Android to gynoid fat ratio greater than 1.0\n* Currently eligible for GLP-1 therapy\n* No diagnosis of Type II diabetes\n\nExclusion Criteria:\n\n* Presence of abnormal ECG findings, including arrhythmias or ischemic changes\n* Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg\n* Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload\n* VO₂ max below 15 ml\u002Fkg\u002Fmin\n* Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads\n* Any contraindications to exercise as defined by ACSM guidelines\n* Musculoskeletal limitations that prevent safe participation in exercise","ALL","40 Years","55 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","Obesity remains a critical public health challenge and is associated with increased rates of morbidity, mortality, and chronic disease worldwide. In recent years, glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide, have emerged as highly effective pharmacological treatments for obesity, producing substantial weight loss and favorable metabolic improvements. These medications are now widely prescribed, with estimates suggesting that nearly 12% of Americans are currently using or have previously used GLP-1 therapies. Despite their demonstrated benefits, growing evidence indicates that GLP-1-associated weight loss may be accompanied by unintended reductions in skeletal muscle and bone mass. This potential side effect is of increasing concern, as muscle and bone are essential for metabolic health, physical function, injury prevention, and recovery from illness or surgical intervention.\n\nLoss of skeletal muscle during weight reduction may negatively impact strength, mobility, insulin sensitivity, and long-term health outcomes. These risks may be further compounded in individuals experiencing reduced physical activity, mechanical unloading, or prolonged caloric deficits. In clinical and surgical populations, such as individuals undergoing orthopedic procedures, mechanical unloading and disuse already predispose patients to muscle and bone atrophy. When combined with pharmacologically induced weight loss, these factors may further hinder recovery, impair functional capacity, and compromise musculoskeletal integrity. As GLP-1 therapies are increasingly adopted across diverse populations, understanding how to preserve lean mass and bone health during treatment has become an important clinical and public health priority.\n\nExercise training, particularly resistance training, combined with appropriate nutritional support, has consistently been shown to preserve and enhance skeletal muscle and bone mass during weight loss. Structured exercise interventions can mitigate sarcopenia and osteopenia while improving muscular strength, cardiorespiratory fitness, metabolic health, and overall physical function. Similarly, individualized dietary counseling, particularly when focused on adequate protein intake and nutrient timing, plays a critical role in supporting muscle protein synthesis and skeletal health during caloric restriction. Together, these lifestyle strategies may not only counteract the potential adverse musculoskeletal effects associated with GLP-1 therapy but also enhance treatment efficacy by improving cardiovascular risk profiles, insulin sensitivity, systemic inflammation, and physical resilience.\n\nDespite the growing use of GLP-1 medications, there remains a limited body of prospective research examining structured lifestyle interventions specifically designed to preserve muscle and bone mass during GLP-1-induced weight loss. Addressing this gap is essential to ensure that pharmacological obesity treatments support long-term health, functional independence, and quality of life. Integrating exercise and nutrition interventions into GLP-1 treatment protocols may represent a scalable and clinically meaningful strategy to optimize outcomes and reduce unintended consequences of rapid weight loss.\n\nThe purpose of this study is to evaluate whether a structured lifestyle intervention combining exercise and individualized nutritional counseling can mitigate skeletal muscle mass loss in obese adults undergoing treatment with GLP-1 receptor agonists. The primary objective of this study is to determine whether participation in a structured 12-week exercise program, in conjunction with individualized dietary counseling, preserves skeletal muscle mass and bone mineral density during GLP-1 therapy. Secondary objectives include assessing changes in muscular strength, cardiorespiratory fitness, and overall functional capacity. Findings from this study aim to inform best practices for integrating lifestyle interventions with pharmacological obesity treatments and to support safer, more effective, and functionally protective approaches to weight management in adults receiving GLP-1 therapy.",[27,28,29,30,31],"GLP - 1","Obesity & Overweight","Muscle Loss","Exercise Intervention","Dietary Assessment",[33,34,35,36],"GLP-1","Semaglutide","obesity","exercise intervention","NOT_YET_RECRUITING","2026-04-21",{"date":40,"type":41},"2026-04-28","ACTUAL",{"date":43,"type":21},"2026-04-06",{"date":45,"type":21},"2026-08-06",{"name":47,"class":48},"William Marsh Rice University","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":16,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":22,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":49},"100431997","can-the-language-environment-analysis-start-program-improve-childrens-readiness-for-school-lena-program-evaluation-100431997","NCT04905381","Can the Language Environment Analysis Start Program Improve Children's Readiness for School? LENA Program Evaluation","Can a Scalable Parenting Program Improve Children's Readiness for School? An Evaluation of the LENA Start Program","Inclusion Criteria:\n\nEligible adult participants include parents who meet all the criteria listed below.\n\n1. Must be 18 years old or older.\n2. Must have a child between 16 and 30 months old as of September 1, 2022.\n3. Must speak English or Spanish as their native language.\n4. Must live in the catchment area of Alief Independent School District. Children of the adult participants enrolled in the study are eligible to participate. The children must meet all the criteria below.\n\n1\\. Must be between 16 and 30 months old as of September 1, 2022 2. Must speak English or Spanish as their native language. 3. Must live in the catchment area of Alief Independent School District.\n\nExclusion Criteria:\n\nAdult participants will not be eligible for this study if they:\n\n* Are NOT 18 years old or older.\n* Do NOT have a child between 16 and 30 months as of September 1, 2022.\n* Do NOT speak English or Spanish as their native language.\n* Do NOT live in the catchment area of Alief Independent School District.\n\nChildren will not be eligible for this study if they:\n\n* Are NOT between 16 and 30 months as of September 1, 2022.\n* Do NOT speak English or Spanish as their native language.\n* Do NOT live in the catchment area of Alief Independent School District.",true,"16 Months","30 Months",{"count":61,"type":21},600,[63],"NA","The objective of the project is to implement the LENA Start Program at the Alief The objective of the project is to implement the LENA Start Program at the Alief Independent School District in Houston, Texas. The purpose of the study is to learn how maternal expectations about language development influence the child's language development. Also, the study will evaluate how much the mothers believe can affect their child's language development. More specifically, the program implementation will serve as a model that other school districts can readily replicate.",[66],"Language Development","RECRUITING",{"date":69,"type":41},"2026-04-24",{"date":71,"type":41},"2022-08-01",{"date":73,"type":21},"2028-12-31",{"name":47,"class":48},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":16,"minAge":82,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":86,"phases":4,"briefSummary":87,"conditions":88,"keywords":91,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},"100352234","validation-of-a-jaundice-diagnostic-and-monitoring-device-for-low-resource-settings-100352234","NCT03866213","Validation of a Jaundice Diagnostic and Monitoring Device for Low-Resource Settings","Validation of a Low-Cost, Point-of-Care Bilirubin Measurement to Diagnose Neonatal Jaundice and Monitor Phototherapy in Hospitals in Sub-Saharan Africa","Inclusion Criteria:\n\n* The patient is currently being treated at Queen Elizabeth Central Hospital or Kamuzu Central Hospital in the neonatal ward.\n* The patient is less than 28 days old (neonate).\n* The patient is deemed to be at risk for jaundice or the patient is undergoing blue light phototherapy for treatment of jaundice.\n* The patient's parent or guardian has provided informed consent for their child to participate.\n\nExclusion Criteria:\n\n* Parent or guardian is unable or unwilling to provide informed consent.\n* The patient is unable to receive a blood draw\u002Fheel stick as determined by their clinician.","0 Days","28 Days",{"count":85,"type":21},1000,"OBSERVATIONAL","A team of researchers at Rice University in partnership with clinicians at Queen Elizabeth Central Hospital created BiliSpec, a low-cost battery-powered reader designed to immediately quantify serum bilirubin levels from a small drop of whole blood applied to a lateral flow strip. The simple and affordable BiliSpec system offers a faster and more cost-effective means to detect neonatal jaundice in under-resourced clinics and determine when phototherapy is needed. The goal of this study is to validate the accuracy of the BiliSpec device in measuring bilirubin levels in neonates relative to the laboratory spectrophotometric bilirubinometer and transcutaneous bilirubinometer measurements.",[89,90],"Hyperbilirubinemia, Neonatal","Jaundice, Neonatal",[92,93,94],"Diagnostic","Point-of-Care","Low-Resource Setting","2024-06-06",{"date":97,"type":41},"2024-06-07",{"date":99,"type":41},"2019-08-01",{"date":101,"type":21},"2024-08-31",{"name":47,"class":48},3,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":111,"maxAge":83,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":49},"100516332","efficacy-of-celsi-warmer-for-the-management-of-hypothermic-newborns-at-the-lagos-university-teaching-hospital-in-lagos-nigeria-100516332","NCT06003140","Efficacy of Celsi Warmer for the Management of Hypothermic Newborns at the Lagos University Teaching Hospital in Lagos, Nigeria","Efficacy of Low-cost Warming Mattress Celsi Warmer for the Management of Hypothermic Newborns at the Lagos University Teaching Hospital in Lagos, Nigeria","Inclusion Criteria:\n\nAny neonate who:\n\n1. Is currently being treated at study location,\n2. Is an inborn admission to the neonatal ward,\n3. Whose parents or guardians provided informed consent,\n4. Whose parents or guardians providing informed consent are 18 years old or older,\n5. Has a current weight of greater than or equal to 1.0 kg and less than or equal to 4.0 kg,\n6. Has been identified as in need of thermal care defined as having a moderate to severe hypothermic temperature (32.0-36.0 °C) as the last temperature recorded in hospital chart, or during recruitment procedures; and\n7. is unable to be enrolled in Kangaroo Mother Care (KMC) for reasons including, but not limited to: a. Mother\u002Fguardian unable or unavailable to provide KMC b. Under observation in the Neonatal Intensive Care Unit (NICU) before transfer to KMC c. No space in KMC d. Clinician's discretion;\n8. May be receiving other medical treatments, including but not limited to, Continuous Positive Airway Pressure (CPAP), oxygen therapy, intravenous (IV) fluids, management and monitoring of common newborn conditions such as hypoglycemia, and\u002For hyperbilirubinemia.\n\nExclusion Criteria:\n\n1. Requires mechanical ventilation;\n2. Is deemed in need of intensive care by the hospital staff who is providing care, including but not limited to: a. neonates with severe anemia and\u002For any suspected hematological disorders, and\u002For b. Neonates with obvious congenital anomalies, and\u002For c. neonates suspected with hypo\u002Fhyperthyroidism or any hormonal disorders;\n3. has been diagnosed with birth asphyxia;\n4. Presents a condition that precludes the use of the temperature sensor and\u002For abdominal belt including but not limited to, known umbilical cord infection, known skin infection;\n5. Whose clinician presents concerns about their participation;\n6. Is receiving treatment that participation in the study would interfere with (e.g. transferring to KMC).","1 Day",{"count":113,"type":21},90,[63],"The prevalence of hypothermia across low-resource settings is high, especially in countries with high neonatal mortality rates. If left untreated, hypothermia can additionally result in a significant comorbidity, and has been linked to a reduction in the effectiveness of treatment for other newborn conditions. Effective thermal care for hypothermic newborns is not widely available in low-resource settings due to cost of consumables and spare parts. In this study, the research team wish to evaluate the efficacy of a novel neonatal warming mattress in treating hypothermic newborns. Warming mattress, 'Celsi Warmer', has been developed by Rice 360 Institute for Global Health Technologies, in conjunction with African clinicians, to be a robust, low-cost, and easy-to-use warming mattress which can address the challenges of hypothermia. This is a single-arm, non-randomized, prospective intervention study. Up to 90 eligible infants at the neonatal wards of the Lagos University Teaching Hospital will be recruited to evaluate the efficacy of Celsi Warmer in rewarming hypothermic newborns. Infants temperature will be monitored during thermal intervention and the performance of the device will be evaluated. The temperatures of each infant will be compared before, during, and after the intervention.",[117],"Neonatal Hypothermia","2024-06-05",{"date":97,"type":41},{"date":121,"type":41},"2023-08-15",{"date":123,"type":21},"2024-10-21",{"name":47,"class":48},""]